NLTX Annual Cash & Cash Equivalents
$37.89 M
-$104.58 M-73.41%
31 December 2022
Summary:
As of January 22, 2025, NLTX annual cash & cash equivalents is $37.89 million, with the most recent change of -$104.58 million (-73.41%) on December 31, 2022. During the last 3 years, it has fallen by -$105.21 million (-73.52%).NLTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly Cash And Cash Equivalents
$25.23 M
-$5.88 M-18.91%
30 September 2023
Summary:
As of January 22, 2025, NLTX quarterly cash and cash equivalents is $25.23 million, with the most recent change of -$5.88 million (-18.91%) on September 30, 2023. Over the past year, it has dropped by -$15.11 million (-37.46%).NLTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -73.4% | -37.5% |
| 3 y3 years | -73.5% | -87.5% |
| 5 y5 years | -27.2% | -70.9% |
NLTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time | -80.3% | -87.5% |
Neoleukin Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2023 | - | $25.23 M(-18.9%) |
| June 2023 | - | $31.11 M(-12.4%) |
| Mar 2023 | - | $35.49 M(-6.3%) |
| Dec 2022 | $37.89 M(-73.4%) | $37.89 M(-6.1%) |
| Sept 2022 | - | $40.34 M(-48.0%) |
| June 2022 | - | $77.53 M(-39.5%) |
| Mar 2022 | - | $128.06 M(-10.1%) |
| Dec 2021 | $142.47 M(-26.0%) | $142.47 M(-8.0%) |
| Sept 2021 | - | $154.92 M(-5.7%) |
| June 2021 | - | $164.24 M(-7.9%) |
| Mar 2021 | - | $178.39 M(-7.4%) |
| Dec 2020 | $192.56 M(+34.6%) | $192.56 M(-4.3%) |
| Sept 2020 | - | $201.15 M(+55.2%) |
| June 2020 | - | $129.60 M(-7.0%) |
| Mar 2020 | - | $139.42 M(-2.6%) |
| Dec 2019 | $143.09 M(+86.0%) | $143.09 M(+115.8%) |
| Sept 2019 | - | $66.31 M(-8.8%) |
| June 2019 | - | $72.70 M(-2.0%) |
| Mar 2019 | - | $74.17 M(-3.6%) |
| Dec 2018 | $76.93 M | $76.93 M(-11.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2018 | - | $86.73 M(-12.5%) |
| June 2018 | - | $99.13 M(+48.8%) |
| Mar 2018 | - | $66.61 M(+28.0%) |
| Dec 2017 | $52.03 M(+61.1%) | $52.03 M(+10.5%) |
| Sept 2017 | - | $47.10 M(+73.5%) |
| June 2017 | - | $27.15 M(+29.8%) |
| Mar 2017 | - | $20.92 M(-35.2%) |
| Dec 2016 | $32.30 M(-18.3%) | $32.30 M(-62.5%) |
| Sept 2016 | - | $86.22 M(+283.7%) |
| June 2016 | - | $22.47 M(-37.0%) |
| Mar 2016 | - | $35.69 M(-9.7%) |
| Dec 2015 | $39.53 M(+165.2%) | $39.53 M(-63.9%) |
| Sept 2015 | - | $109.37 M(+633.3%) |
| June 2015 | - | $14.92 M(+4.4%) |
| Mar 2015 | - | $14.28 M(-4.2%) |
| Dec 2014 | $14.91 M(+35.4%) | $14.91 M(-6.1%) |
| Sept 2014 | - | $15.87 M(-11.3%) |
| June 2014 | - | $17.90 M(-66.2%) |
| Mar 2014 | - | $52.92 M(+380.8%) |
| Dec 2013 | $11.01 M(+450.2%) | $11.01 M |
| Dec 2012 | $2.00 M | - |
FAQ
- What is Neoleukin Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual cash & cash equivalents year-on-year change?
- What is Neoleukin Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Neoleukin Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of NLTX is $37.89 M
What is the all time high annual cash & cash equivalents for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual cash & cash equivalents is $192.56 M
What is Neoleukin Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, NLTX annual cash & cash equivalents has changed by -$104.58 M (-73.41%)
What is Neoleukin Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NLTX is $25.23 M
What is the all time high quarterly cash and cash equivalents for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly cash and cash equivalents is $201.15 M
What is Neoleukin Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, NLTX quarterly cash and cash equivalents has changed by -$15.11 M (-37.46%)